VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Browse by Series:

Managing Avelumab Side Effects in Patients With Merkel Cell Carcinoma

Howard Kaufman, MD
Published: Thursday, May 04, 2017



Howard L. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, discusses the adverse event profile of avelumab (Bavencio) for patients with Merkel cell carcinoma.
Slider Left
Slider Right


Howard L. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, discusses the adverse event profile of avelumab (Bavencio) for patients with Merkel cell carcinoma.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x